Pharsight

1. Aponvie patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561229	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9808465	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10500208	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974793	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974742	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US10953018	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974794	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10624850	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US11744800	HERON THERAPS INC	Methods of use of emulsion formulations of an NK-1 receptor antagonist	Sep, 2035 (11 years from now)
US11173118	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
32MG/4.4ML (7.2MG/ML)	EMULSION;INTRAVENOUS	Prescription

APONVIE family patents

2. Cinvanti patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974793	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US9974794	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US11744800	HERON THERAPS INC	Methods of use of emulsion formulations of an NK-1 receptor antagonist	Sep, 2035 (11 years from now)
US9974742	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US11173118	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US9561229	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10953018	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10624850	HERON THERAPS INC	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	Sep, 2035 (11 years from now)
US9808465	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)
US10500208	HERON THERAPS INC	Emulsion formulations of aprepitant	Sep, 2035 (11 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
130 mg/18 mL	29 Apr, 2022	1		18 Sep, 2035

Strength	Dosage	Availability
130MG/18ML (7.2MG/ML)	EMULSION;INTRAVENOUS	Prescription

CINVANTI family patents

3. Sustol patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6790458	HERON THERAPS INC	Pharmaceutical compositions using semi-solid delivery vehicle	May, 2021 (2 years ago)
US6613355	HERON THERAPS INC	Semi-solid delivery vehicle and pharmaceutical compositions	Jun, 2021 (2 years ago)
US9913910	HERON THERAPS INC	Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron	Sep, 2024 (4 months from now)
US10357570	HERON THERAPS INC	Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron	Sep, 2024 (4 months from now)
US8252305	HERON THERAPS INC	Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron	Sep, 2024 (4 months from now)
US8252304	HERON THERAPS INC	Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron	Sep, 2024 (4 months from now)
US8715710	HERON THERAPS INC	Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron	Sep, 2024 (4 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Aug 09, 2019

Drugs and Companies using GRANISETRON ingredient

Market Authorisation Date: 09 August, 2016

Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting

Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
10MG/0.4ML (10MG/0.4ML)	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

SUSTOL family patents

4. Zynrelef Kit patents expiration

Patent	Proceeding Filing Date	Status	Respondent

US11083730	May, 2020	Decision	Heron Therapeutics, Inc.
US11083797	May, 2020	Decision	Heron Therapeutics, Inc.
US10898575	December, 2019	Decision	Heron Therapeutics, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253504	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (9 years from now)
US9592227	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (9 years from now)
US9744163	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (9 years from now)
US10398686	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (9 years from now)
US9913909	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (9 years from now)
US11083730	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US9801945	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US9694079	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US10098957	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US10213510	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US10632199	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US10898575	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US10980886	HERON THERAPS INC	Compositions of a polyorthoester and an organic acid excipient	Apr, 2035 (10 years from now)
US11413350	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US11083797	HERON THERAPS INC	Long-acting polymeric delivery systems	Apr, 2035 (10 years from now)
US11844837	HERON THERAPS INC	Compositions of a polyorthoester and an organic acid excipient	Apr, 2036 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 12, 2024
New Indication(I-933)	Jan 23, 2027

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR